PE20211455A1 - Moduladores del receptor nmda espiro-lactama y usos de los mismos - Google Patents

Moduladores del receptor nmda espiro-lactama y usos de los mismos

Info

Publication number
PE20211455A1
PE20211455A1 PE2020001149A PE2020001149A PE20211455A1 PE 20211455 A1 PE20211455 A1 PE 20211455A1 PE 2020001149 A PE2020001149 A PE 2020001149A PE 2020001149 A PE2020001149 A PE 2020001149A PE 20211455 A1 PE20211455 A1 PE 20211455A1
Authority
PE
Peru
Prior art keywords
alkyl
group
spiro
independently selected
lactama
Prior art date
Application number
PE2020001149A
Other languages
English (en)
Spanish (es)
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of PE20211455A1 publication Critical patent/PE20211455A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2020001149A 2018-01-31 2019-01-31 Moduladores del receptor nmda espiro-lactama y usos de los mismos PE20211455A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624218P 2018-01-31 2018-01-31
US201862718107P 2018-08-13 2018-08-13
PCT/US2019/016098 WO2019152678A1 (en) 2018-01-31 2019-01-31 Spiro-lactam nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
PE20211455A1 true PE20211455A1 (es) 2021-08-05

Family

ID=65494516

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001149A PE20211455A1 (es) 2018-01-31 2019-01-31 Moduladores del receptor nmda espiro-lactama y usos de los mismos

Country Status (15)

Country Link
US (1) US20210047324A1 (cg-RX-API-DMAC7.html)
EP (1) EP3746442A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021512109A (cg-RX-API-DMAC7.html)
KR (1) KR20200115610A (cg-RX-API-DMAC7.html)
CN (1) CN112218866A (cg-RX-API-DMAC7.html)
AU (1) AU2019215049A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020015666A2 (cg-RX-API-DMAC7.html)
CA (1) CA3089559A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020001990A1 (cg-RX-API-DMAC7.html)
IL (1) IL276330A (cg-RX-API-DMAC7.html)
MX (1) MX2020008106A (cg-RX-API-DMAC7.html)
PE (1) PE20211455A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551140A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007251XA (cg-RX-API-DMAC7.html)
WO (1) WO2019152678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898861C (en) 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190501A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN109890825B (zh) 2016-08-01 2022-03-11 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
AU2024354932A1 (en) * 2023-10-03 2026-04-09 Revolution Medicines, Inc. Synthesis of ras inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011003015A (es) * 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
SG10201501050RA (en) * 2010-02-11 2015-04-29 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技(上海)有限公司 一种制备二氮杂螺环化合物的方法
JP6419087B2 (ja) * 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系nmda受容体モジュレーターおよびその使用
SG11201505937SA (en) * 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
CA2898861C (en) * 2013-01-29 2021-07-20 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2014120784A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN105308049A (zh) * 2013-01-29 2016-02-03 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
EP3277690B1 (en) * 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
PE20190174A1 (es) * 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) * 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
AR110988A1 (es) * 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Also Published As

Publication number Publication date
AU2019215049A1 (en) 2020-09-17
BR112020015666A2 (pt) 2021-02-23
EP3746442A1 (en) 2020-12-09
MX2020008106A (es) 2020-09-25
PH12020551140A1 (en) 2021-05-31
JP2021512109A (ja) 2021-05-13
CN112218866A (zh) 2021-01-12
JP2024019396A (ja) 2024-02-09
SG11202007251XA (en) 2020-08-28
WO2019152678A1 (en) 2019-08-08
CL2020001990A1 (es) 2021-03-26
IL276330A (en) 2020-09-30
US20210047324A1 (en) 2021-02-18
KR20200115610A (ko) 2020-10-07
CA3089559A1 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
PE20241131A1 (es) Modulador del regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador
PE20190503A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2020001546A1 (es) Compuestos de 4-azaindol.
MX2023010043A (es) Moduladores del receptor de androgenos y metodos para su uso.
PE20210454A1 (es) Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos
MX2020006460A (es) Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
CO2020001220A2 (es) Compuestos, composiciones y métodos
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20221457A1 (es) Degradadores de moleculas pequenas de helios y procedimientos de uso
CO2021010490A2 (es) Compuestos, composiciones y métodos
UY37310A (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
PE20180462A1 (es) Moduladores cot y metodos de uso de los mismos
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
AR109561A1 (es) Compuestos modulares de receptores tipo toll
MX2021009673A (es) Moduladores de ror-gamma.
CO2022002781A2 (es) Receptores agonistas no peptídicos de somatostatina tipo 5 y usos de los mismos
PE20191495A1 (es) Piridonamidas como moduladores de canales de sodio
PE20181491A1 (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20190504A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CR20190124A (es) Inhibidores de ssao de aminopirimidina
PE20170324A1 (es) Anticuerpos dirigidos contra cd127
AR054320A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas
MX2020003666A (es) Compuestos y composiciones para el tratamiento de trastornos hematologicos.
MX2019011904A (es) Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos.
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano